X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Nextstellis is a novel combination medication comprising of drospirenone (DRSP) and estetrol (E4), indicated for use by women of reproductive age to prevent pregnancy.
Lead Product(s): Drospirenone,Estetrol
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nextstellis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: OLIC
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 12, 2024
Details:
Lupin has completed the acquisition of two well-known brands, Aarane (sodium cromoglicate) in Germany and Nalcrom (cromoglicic acid) in Canada and the Netherlands, from Sanofi.
Lead Product(s): Sodium Cromoglicate,Bronchodil
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Aarane
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition June 05, 2024
Details:
Rymti (etanercept-biosimilar) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged 2 years or older, psoriatic arthritis, ankylosing spondylitis & plaque psoriasis.
Lead Product(s): Etanercept
Therapeutic Area: Immunology Product Name: Rymti
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Sandoz B2B
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2024
Details:
Ganirelix Acetate-Generic is a synthetic decapeptide with high antagonistic 6 activity against naturally occurring GnRH. It is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
Lead Product(s): Ganirelix
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Ganirelix Acetate-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2024
Details:
BromSite-Generic (bromfenac) acts by inhibiting Cox-1 and 2. It is indicated for the treatment of postoperative inflammation and prevention of ocular pain in patients undergoing cataract surgery.
Lead Product(s): Bromfenac
Therapeutic Area: Ophthalmology Product Name: BromSite-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2024
Details:
Inderal-Generic (propranolol) is a β-adrenoceptors antagonist. It is now approved for the treatment of hypertension, angina pectoris, migraine, hypertrophic subaortic stenosis.
Lead Product(s): Propranolol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Inderal-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 14, 2024
Details:
RLD Chantix (varenicline) is a nAChRα4&β2 (Neuronal acetylcholine receptor; alpha4/beta2) agonist, small molecule drug. It is approved for the treatment of smoking cessation.
Lead Product(s): Varenicline Tartrate
Therapeutic Area: Psychiatry/Psychology Product Name: RLD Chantix
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2024
Details:
Through th acquisition, Lupin expand its portfolio of accretive established products in Europe and Canada, including Xopenex (levalbuterol HCl), a short-acting β₂ adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease.
Lead Product(s): Levalbuterol Hydrochloride
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Xopenex
Highest Development Status: ApprovedProduct Type: Small molecule
Recipient: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 23, 2023
Details:
Vilfuro-G (vilanterol, fluticasone furoate & glycopyrronium bromide) is world's first fixed-dose triple combination drug which is approved for the treatment of chronic obstructive pulmonary disease (COPD).
Lead Product(s): Vilanterol Trifenatate,Fluticasone Furoate,Glycopyrronium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Vilfuro-G
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2023
Details:
Fluconazole, the first of a new subclass of synthetic triazole antifungal agents, is available as tablets for oral administration, which is indicated for the treatment of Vaginal candidiasis.
Lead Product(s): Fluconazole
Therapeutic Area: Infections and Infectious Diseases Product Name: Diflucan-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
